全文获取类型
收费全文 | 602篇 |
免费 | 15篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 11篇 |
妇产科学 | 3篇 |
基础医学 | 24篇 |
口腔科学 | 1篇 |
临床医学 | 16篇 |
内科学 | 42篇 |
皮肤病学 | 4篇 |
神经病学 | 15篇 |
特种医学 | 57篇 |
外科学 | 29篇 |
综合类 | 13篇 |
预防医学 | 358篇 |
眼科学 | 3篇 |
药学 | 24篇 |
肿瘤学 | 17篇 |
出版年
2019年 | 5篇 |
2016年 | 3篇 |
2014年 | 4篇 |
2013年 | 10篇 |
2012年 | 7篇 |
2011年 | 8篇 |
2010年 | 5篇 |
2009年 | 12篇 |
2008年 | 15篇 |
2007年 | 13篇 |
2006年 | 8篇 |
2005年 | 11篇 |
2004年 | 6篇 |
2003年 | 5篇 |
2001年 | 8篇 |
1999年 | 4篇 |
1998年 | 7篇 |
1997年 | 13篇 |
1996年 | 10篇 |
1995年 | 12篇 |
1994年 | 8篇 |
1993年 | 15篇 |
1992年 | 3篇 |
1990年 | 4篇 |
1989年 | 7篇 |
1988年 | 10篇 |
1987年 | 11篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1981年 | 3篇 |
1977年 | 3篇 |
1938年 | 4篇 |
1937年 | 8篇 |
1934年 | 6篇 |
1932年 | 4篇 |
1931年 | 16篇 |
1930年 | 26篇 |
1929年 | 30篇 |
1928年 | 28篇 |
1927年 | 13篇 |
1926年 | 16篇 |
1925年 | 14篇 |
1924年 | 26篇 |
1923年 | 25篇 |
1922年 | 20篇 |
1921年 | 22篇 |
1920年 | 22篇 |
1919年 | 25篇 |
1918年 | 21篇 |
1915年 | 3篇 |
排序方式: 共有618条查询结果,搜索用时 0 毫秒
61.
62.
63.
64.
65.
W MacNee J J Connaughton G B Rhind M D Hayhurst N J Douglas A L Muir D C Flenley 《The American review of respiratory disease》1986,134(3):559-565
Almitrine bismesylate is a new, orally administered, respiratory stimulant that improves arterial blood gas tensions in patients with chronic bronchitis and emphysema, and it may have an effect on the pulmonary circulation and on right ventricular performance. We have, therefore, compared the effects of Almitrine with those of oxygen (given as 3 L/min by nasal prongs) on arterial blood gas tensions, mean pulmonary arterial pressure (Ppa), and right ventricular ejection fraction (RVEF) measured both at rest and during exercise in patients with chronic hypoxemia caused by chronic bronchitis and emphysema. Arterial oxygen tension improved significantly both at rest and during exercise after either 100 mg Almitrine by mouth or when breathing oxygen, both at rest and during exercise. Almitrine increased the mean Ppa at rest from 22 +/- 4 to 35 +/- 5 mmHg (p less than 0.001), and mean Ppa rose further during exercise from 38 +/- 5 mmHg before Almitrine to 49 +/- 7 mmHg (p less than 0.001) after Almitrine. In contrast, oxygen breathing did not change Ppa when at rest but reduced the amount of rise in Ppa during exercise. The change in Ppa after Almitrine correlated with the plasma Almitrine concentration (r = 0.69, p less than 0.05) and was associated with a fall in RVEF at rest from 0.38 +/- 0.03 to 0.32 +/- 0.02 (p less than 0.001). In 5 of the patients who received 50 mg of Almitrine by mouth twice daily for 3 months, the Ppa both at rest and during exercise remained significantly higher than in the control study before receiving Almitrine, but RVEF was unchanged.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
66.
Cyclic neutropenia (CN): a clue to the control of granulopoiesis 总被引:2,自引:0,他引:2
A simple quantitative feedback model of granulopoiesis is presented and discussed within the framework of existing data on granulopoiesis in both normals and patients with cyclic neutropenia (CN). The model assumes that the controlled compartment is the bone marrow pool of mature neutrophils (PMNs), which sends a negative feedback signal to the mitotic pool of early granulocyte precursors (i.e., CFU-C, myeloblasts, etc.) thus controlling the granulocyte production rate. Three parameters are found to play important roles in determining the response of the system to perturbations. These are: TM, the granulocyte maturation time; a, a parameter reflecting the strength of the negative feedback exerted by mature PMNs on the granulocyte production rate; and b, a parameter describing the leakiness of the bone marrow for PMN egress. It is shown that depending on the relative magnitudes of a and b, the system will either respond to perturbations with a damped oscillation (a less than b: the normal state) or with a sustained oscillation (a greater than b: the CN state). In both cases, the oscillation period is found to approximately equal 2TM. Deductions of the values of a, b, and TM from experimental data are consistent with the predictions of the model and show an increased value of a in CN relative to the normal state. This suggests an overly active feedback mechanism as the pathophysiologic basis of CN. In addition, the model can explain how various therapeutic agent correct CN and also provides insight into why other hematologic cell lines and CSA oscillate in CN. 相似文献
67.
Matthew GK Benesch Rongrong Wu Gopal Menon Kazuaki Takabe 《American journal of cancer research》2022,12(12):5403
Outcomes in pancreatic ductal adenocarcinoma (PDAC) are known to be worse in tumors with high integrin β1 expression, but targeted monotherapy against this integrin has not been effective. Seven other beta integrins are expressed in mammalian biology and they are known to have overlapping and compensatory signaling in biological systems. However, their roles in PDAC are poorly understood and have not been systematically compared to integrin β1 biology. In this study, we analyzed the clinical outcomes against beta integrin 1-8 (ITGB1-8) expression in PDAC samples from two large independent cohorts, The Cancer Genome Atlas (TCGA) and . Biological function and tumor microenvironment composition were studied using Gene Set Enrichment Analysis and xCell. Expression of all eight beta integrins is significantly increased in PDACs relative to normal pancreatic tissues (all P<0.001). ITGB1, 2, 5, and 6 have similarly enriched gene patterns related to transforming growth factor (TGF)-β, epithelial mesenchymal transition, inflammation, stemness, and angiogenesis pathways. Homologous recombination defects and neoantigens are increased in high-ITGB4, 5, and 6 tumors, with decreased overall survival in high-ITGB1, 5, and 6 tumors compared to low expression tumors (hazard ratios 1.5-2.0). High-ITGB1, 2, and 5 tumors have increased fibroblast infiltration (all P<0.01) while endothelial cells are increased in high-ITGB2 and 3 tumors (all P<0.05). Overall, beta integrin expression does not correlate to immune cell populations in PDACs. Therefore, while all beta integrins are overexpressed in PDACs, they exert differential effects on PDAC biology. ITGB2, 5, and 6 have a similar profile to ITGB1, suggesting that future research in PDAC integrin therapy needs to consider the complementary signaling profiles mediated by these integrins. GSE21501相似文献
68.
Emery R. Hayhurst 《American journal of public health》1946,36(9):1067-1068
69.
70.